Cargando…
Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients
BACKGROUND: Antibody levels against SARS-CoV-2 can be used as an indicator of recent or past vaccination or infection. However, the prognostic value of antibodies targeting the receptor binding protein (anti-RBD) in hospitalized patients is not widely reported. PURPOSE: Determine prognostic impact o...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215841/ https://www.ncbi.nlm.nih.gov/pubmed/35755860 http://dx.doi.org/10.2147/IJGM.S370080 |
_version_ | 1784731297502986240 |
---|---|
author | Madanat, Luai Sager, Melinda O’Connor, Daniel Thapa, Bijaya Aggarwal, Nishant Ghimire, Bipin Lauter, Carl Maine, Gabriel N Sims, Matthew Halalau, Alexandra |
author_facet | Madanat, Luai Sager, Melinda O’Connor, Daniel Thapa, Bijaya Aggarwal, Nishant Ghimire, Bipin Lauter, Carl Maine, Gabriel N Sims, Matthew Halalau, Alexandra |
author_sort | Madanat, Luai |
collection | PubMed |
description | BACKGROUND: Antibody levels against SARS-CoV-2 can be used as an indicator of recent or past vaccination or infection. However, the prognostic value of antibodies targeting the receptor binding protein (anti-RBD) in hospitalized patients is not widely reported. PURPOSE: Determine prognostic impact of SARS-CoV-2 antibody quantification at the time of admission on clinical outcomes in hospitalized COVID-19 patients. METHODS: We conducted a pilot observational study on patients hospitalized with SARS-CoV-2 infection to determine the prognostic impact of antibody quantitation within the first two days of admission. Anti-nucleocapsid IgG (anti-N) and Anti-RBD levels were measured. Anti-RBD level of 500 AU/mL was used as a cutoff to stratify patients. Spearman’s rank Coefficient (r(s)) was used to demonstrate association. RESULTS: Of the 26 patients included, those who were vaccinated more frequently tested positive for Anti-RBD (100% vs 46.2%, P = 0.005) with higher median titer level (623 vs 0, P = 0.011) compared to unvaccinated patients. Anti-N positivity was more frequently seen in unvaccinated patients (53.9% vs 7.7%, P = 0.03). Anti-RBD levels >500 were associated with lower overall hospital length of stay (LOS)(5 vs 10 days, P = 0.046). The analysis employing a Spearman Rank coefficient demonstrated a strong negative correlation between anti-S titer and LOS (r(s)=−.515, p = 0.007) and a moderate negative correlation with oxygen needs (r(s) =−.401, p = 0.042). CONCLUSION: Anti-RBD IgG levels were associated with lower LOS and oxygen needs during hospitalization. Further studies are needed to determine if levels on admission can be used as a prognostic indicator. |
format | Online Article Text |
id | pubmed-9215841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-92158412022-06-23 Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients Madanat, Luai Sager, Melinda O’Connor, Daniel Thapa, Bijaya Aggarwal, Nishant Ghimire, Bipin Lauter, Carl Maine, Gabriel N Sims, Matthew Halalau, Alexandra Int J Gen Med Short Report BACKGROUND: Antibody levels against SARS-CoV-2 can be used as an indicator of recent or past vaccination or infection. However, the prognostic value of antibodies targeting the receptor binding protein (anti-RBD) in hospitalized patients is not widely reported. PURPOSE: Determine prognostic impact of SARS-CoV-2 antibody quantification at the time of admission on clinical outcomes in hospitalized COVID-19 patients. METHODS: We conducted a pilot observational study on patients hospitalized with SARS-CoV-2 infection to determine the prognostic impact of antibody quantitation within the first two days of admission. Anti-nucleocapsid IgG (anti-N) and Anti-RBD levels were measured. Anti-RBD level of 500 AU/mL was used as a cutoff to stratify patients. Spearman’s rank Coefficient (r(s)) was used to demonstrate association. RESULTS: Of the 26 patients included, those who were vaccinated more frequently tested positive for Anti-RBD (100% vs 46.2%, P = 0.005) with higher median titer level (623 vs 0, P = 0.011) compared to unvaccinated patients. Anti-N positivity was more frequently seen in unvaccinated patients (53.9% vs 7.7%, P = 0.03). Anti-RBD levels >500 were associated with lower overall hospital length of stay (LOS)(5 vs 10 days, P = 0.046). The analysis employing a Spearman Rank coefficient demonstrated a strong negative correlation between anti-S titer and LOS (r(s)=−.515, p = 0.007) and a moderate negative correlation with oxygen needs (r(s) =−.401, p = 0.042). CONCLUSION: Anti-RBD IgG levels were associated with lower LOS and oxygen needs during hospitalization. Further studies are needed to determine if levels on admission can be used as a prognostic indicator. Dove 2022-06-18 /pmc/articles/PMC9215841/ /pubmed/35755860 http://dx.doi.org/10.2147/IJGM.S370080 Text en © 2022 Madanat et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Short Report Madanat, Luai Sager, Melinda O’Connor, Daniel Thapa, Bijaya Aggarwal, Nishant Ghimire, Bipin Lauter, Carl Maine, Gabriel N Sims, Matthew Halalau, Alexandra Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients |
title | Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients |
title_full | Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients |
title_fullStr | Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients |
title_full_unstemmed | Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients |
title_short | Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients |
title_sort | prognostic value of sars-cov-2 anti-rbd igg antibody quantitation on clinical outcomes in hospitalized covid-19 patients |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215841/ https://www.ncbi.nlm.nih.gov/pubmed/35755860 http://dx.doi.org/10.2147/IJGM.S370080 |
work_keys_str_mv | AT madanatluai prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients AT sagermelinda prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients AT oconnordaniel prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients AT thapabijaya prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients AT aggarwalnishant prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients AT ghimirebipin prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients AT lautercarl prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients AT mainegabrieln prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients AT simsmatthew prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients AT halalaualexandra prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients |